This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Walsh — Among FDA-regulated establishments and stakeholders, there is one word that makes everyone go on edge – the dreaded FDA “inspection.” In FY2023, FDA conducted over 1000 inspections under the BIMO program. We also detail some of our recommended best practices to achieve success when FDA comes knocking.
Schwartz — FDA recently published a Federal Register (FR) Notice [ Docket No. FDA-2024-N-3945 ] announcing the publication of a draft strategy document, for public comment, outlining specific actions FDA plans to take to facilitate the use of innovative manufacturing technologies.
In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. The focus on identifying the ideal drug dosage is not new.
Schwartz In early April, Cellares became the first company to announce receipt of an Advanced Manufacturing Technology (AMT) designation from FDA. 356l), directed FDA to establish the AMT Designation Pilot Program. The law directed FDA to issue guidance regarding the implementation of the program, which was finalized in December 2024.
The FDA emphasizes that intrahepatic bile duct cancers have an estimated 5-year relative survival rate and unresectable, locally advanced or metastatic iCCAs, such as those for which LYTGOBI is conditionally approved, is a serious public health concern where surgery is not an option and treatment for the condition involves serious risks.
The US Food and Drug Administration (FDA) recently highlighted data integrity issues concerning premarket submissions received for medical devices. This was communicated in a Letter to Industry (medical devices) published by the agency on 20 February 2024.
The webinar largely consisted of summarizing the general requirements under Parts 803, 806 and 820.198, which we do not reproduce here ( but see another of our prior blog posts discussing these requirements and their applicable to LDTs in greater detail; you can also find FDA’s slides from the webinar here ).
Promotional labeling is generally any labeling other than FDA-required labeling that is devised for the promotion of a product, as well as other functions, and can include printed, audio, or visual matter that describes the product. l)(1) (e.g., l)(1) (e.g.,
The primary vehicle for FDA to request cybersecurity information in premarket submissions has been guidance documents. However, FDA’s legal standing to insist on cybersecurity features, especially within the substantial equivalence paradigm, has been questionable. It applies whether the software is the entire device (i.e.,
Certainly, navigating FDA, EMA, or OPDP guidelines can be daunting. Social listening tools can also help identify patient sentiment, gaps in provider communication, or competitive intelligence. A 2024 Accenture study reported that 68% of U.S. FAQs Is digital marketing in pharma compliant with FDA regulations? Absolutely.
Certainly, navigating FDA, EMA, or OPDP guidelines can be daunting. Social listening tools can also help identify patient sentiment, gaps in provider communication, or competitive intelligence. A 2024 Accenture study reported that 68% of U.S. FAQs Is digital marketing in pharma compliant with FDA regulations? Absolutely.
on July 17, 2024 for a social media post published by Instagram influencer Brittany Mahomes (who has 2 million Instagram followers) about AUVI-Q (epinephrine injection, USP) that “entirely omit[ed] all risk information” about the drug. August 2024 Untitled Letter to Mirati Therapeutics Inc.
District Court for the District of Columbia (“DDC”) against FDA alleging that the Agency’s structure of NDA review is unconstitutional (by our count the 31st Vanda litigation against FDA or another government entity in the last five years, including appeals). In January 2024, the U.S. II, § 2, cl.
Livornese — On February 6, 2024, FDA issued a draft guidance titled Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act. By Véronique Li, Senior Medical Device Regulation Expert & Deborah L.
11-13 Recent reports from US Food and Drug Administration (FDA) authors concluded that AI can usefully be applied to some aspects of ICSR (individual Case Safety Reports) processing and evaluation, but the performance of current AI algorithms requires a human-in-the-loop to ensure good quality. 2024 [cited 2025Feb]. 2024 ;234:3418.
We are going to make this country the hub of biotechnology innovation,” RFK Jr said during a US Food and Drug Administration (FDA) roundtable on cell and gene therapy on 5 June. We may still continue to send you service-related and other non-promotional communications. Bhattacharya centred his remarks around sickle cell anaemia.
Mullen — On June 2, 2023, FDA issued the latest version of its guidance on Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program. The document provides minor updates on procedures, incorporating recent developments and experiences in how FDA interacts with industry.
Originally approved for children in 2021, the FDA updated the drug’s label in January this year to include adults. A drug with a recent approval extension in the US, though not the UK, was Supernus Pharmaceuticals’ Qelbree (viloxazine extended-release capsules). ADHD treatments were in the political crosshairs in the US recently.
Baumhardt, Senior Medical Device Regulation Expert — FDA recently issued a draft guidance on Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program , which included some changes over the existing guidance which could have a negative impact on future pre-submissions.
Newberger — We have written many posts ( here , here , here , and more) about the impact of the reductions in force (RIFs) on various activities across FDA. We note that the webpage for the Office of Management is still functional, but has not been updated since January 2024.) By Jennifer D.
Small Dispensers and the 6/12/2024FDA Announcement Concerning DSCSA This week’s article on the recent DSCSA postponement comes from PRS Pharmacy Services. If the FDA or another regulator requests DSCSA transaction data, the DSCSA regulations give you up to 48 hours to respond. The original article can be found HERE.
Mullen — On February 20, 2024, FDA issued a letter to the medical device industry ( link ) warning medical device firms of recent FDA concerns related to fraudulent and unreliable laboratory testing data in premarket submissions. By Adrienne R. Lenz, Principal Medical Device Regulation Expert & Allyson B.
Over the past five years, the medium has grown exponentially as digital health communication strategies evolved. It offers pharma brands a platform to speak clearly while still complying with FDAcommunication guidelines. Conclusion and Key Takeaways Healthcare podcasts are reshaping how pharmaceutical brands communicate.
Food and Drug Administration (FDA) to treat opioid use disorder and alcohol use disorder. Communicating openly with your healthcare team about all medical conditions you have and medications you take is the best way to identify potential naltrexone interactions. It comes as an oral tablet and intramuscular (IM) injection.
In his conference keynote address , Arun Rao—the Deputy Assistant Attorney General for DOJ’s Consumer Protection Branch—provided an overview of DOJ’s year in FDA enforcement. We’ve blogged on VSDs previously here and here , as the application of the VSD for FDA-regulated industry has been vexing.
A digital patient monitoring tool developed by UK company CyberLiver has been given a breakthrough designation by the FDA for out-of-hospital management of patients with cirrhosis at risk of complications. The post Digital tool cuts hospital readmissions in cirrhosis patients appeared first on.
In addition, concerning any practitioner-patient telemedicine relationships that have been or will be established up to November 11, 2023, all telemedicine flexibilities concerning prescribing of controlled substances established during the COVID-19 PHE will also be extended for one year – through November 11, 2024. 1307.41and 42 C.F.R.
The oral medication, approved by the Food and Drug Administration ( FDA ) in 1971, works as an antimicrobial , killing the bacterial cells that caused the UTI. A 2024 comparative study found that cephalexin for the treatment of UTIs had a failure rate of 8.3% UTIs are more common in women than men. Is cephalexin good for UTIs ?
Last year, Novartis began with a win in January, as the US Court of Appeals affirmed the validity of Gilenya’s patent, allowing the company to sue a competitor generics company for filing for FDA approval for its Gilenya generic. Gilenya is an oral medication for multiple sclerosis. Fighting Entresto generics.
For patients, omnichannel marketing is about seamless communication. Regulatory bodies like the FDA and EMA enforce stringent advertising guidelines, ensuring that pharma companies maintain transparency and ethical marketing practices. Meeting HCPs where they are, whether its in a clinical setting or browsing research articles online.
The FDA has approved these devices for mild to moderate hearing loss. In 2024, the household income limit to qualify is under $27,180 for an individual or under $36,620 for a two-person household. In 2024, this is $30,120 for an individual and $40,880 for a couple. There are a few options to consider.
While DSCSA (the Drug Supply Chain Security Act) enforcement is postponed until November 2024, it is critical to move forward in becoming compliant sooner rather than later. When regulators, such as the FDA, request information about a specific drug product, your pharmacy must be able to promptly provide the necessary traceability data.
Renowned figures such as Elon Musk and Oprah Winfrey openly discuss their experiences with the drug, sparking interest beyond its FDA-approved use. Global Expansion and Negotiation Challenges for Eli Lilly Eli Lilly’s future plans encompass the expansion of its weight-loss drug Mounjaro to new countries in 2024.
FDA is expected to provide initial feedback on the data submitted by July 2024, with further data to be collected and analysed over the next two years. What is the main reason submission of the DVA qualification to FDA is significant for future clinical trials?
There are seven FDA-approved Humira biosimilars, of which Amgen’s Amjevita will be launched in January. Samsung Bioepis and Organon previously stated that Hadlima's interchangeability data should be ready in 2024. While small molecule drugs can be remade into identical generics, biologics are more complex.
Some of its FDA-approved competitors include: Patents7 Eli Lilly carries big expectations from Trulicity to boost its revenue. Those with Medicare or Medicaid coverage are not eligible. Trulicity Competitors6 There are many other alternative types of diabetes medications present in the market that gives tough opposition to Trulicity.
PQA offers a competitive Advanced Pharmacy Practice Experiential (APPE) Rotation for pharmacy students, which provides experiential learning opportunities in non-profit association management, medication use quality education, communications, research and performance measurement. Applications for the 2024-25 year are now being accepted.
Covid-19 vaccines from Moderna and Pfizer /BioNTech, which use lipid nanoparticles, became the only two FDA-approved vaccines for almost all ages. However, after a period of slow movement in the field, the FDA approved the first nanodrug, Doxil, for Kaposi sarcoma in 1995. GlobalData is the parent company of Pharmaceutical Technology.
I think the most important thing is making a good team and also good communication within that team is very important. RudaCure’s leading product in development RCI001, is an ophthalmic solution for the treatment of Dry Eye Disease looking to start Phase 1 trials in South Korea and Phase 2 FDA clinical trials by 2023.
In addition, this article provides an explanation of the purpose and expected outcomes from the survey, subsequent plans for communicating the results from the survey across ISPE, and development of concrete proposals to address the sources of challenges and barriers to innovation. 22 June 2023. link] 16 US Food and Drug Administration.
Article Posted 14 April 2024 What is Clostridioides difficile ? These advancements are evidenced by the two FDA-approved FMT products available for rCDI prevention: Rebyota (Fecal Microbiota, Live-jslm) and Vowst (Fecal Microbiota Spores, Live-brpk). Rebyota, a solution delivered via enema, was the first FMT product to be FDA-approved.
Plecanatide : This is one of the newest medications for IBS-C that has been approved by the FDA. Tenapanor : Tenapanor was approved by the FDA in September of 2019 for IBS-C. 82] Many of them do so by helping the gut to communicate with the central nervous system, essentially retraining it to move more efficiently. freece.com.
On March 5, 2024, the U.S. Food and Drug Administration (FDA) approved the first over-the-counter (OTC) continuous glucose monitor (CGM). Especially for people who are managing diabetes, the Stelo GCM should be used in communication with a healthcare team. Produced by DexCom, Inc., When will Stelo be available?
The US Food and Drug Administration (FDA) approved Ferring Pharmaceuticals’ Prior-Approval Supplement (PAS) to the Biologics License Application (BLA) for the bladder cancer gene-therapy Adstiladrin (nadofaragene firadenovec). The company aims to then increase supplies in 2024. Please check your email to download the Report.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content